Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitorHAJJI, N; MATEOS, S; PASTOR, N et al.Mutation research. Genetic toxicology and environmental mutagenesis. 2005, Vol 583, Num 1, pp 26-35, issn 1383-5718, 10 p.Article

Proceedings/Aclarubicin, a new drug in cancer treatment, symposium: 3rd. European conference on clinical oncology and cancer nursing, Stockholm, June 17 th., 1985GAHRTON, G.Scandinavian journal of haematology. Supplementum. 1987, Vol 38, Num 47, issn 0080-6722, 76 p.Conference Proceedings

PREPARATION OF 4- AND 6-O-METHYL-ACLACINOMYCIN DERIVATIVES AND THEIR ANTITUMOR ACTIVITIESTANAKA H; YOSHIOKA T; SHIMAUCHI Y et al.1981; J. ANTIBIOT.; ISSN 0021-8820; JPN; DA. 1981; VOL. 34; NO 7; PP. 905-908; BIBL. 5 REF.Article

EFFECTS OF ACLACINOMYCIN-A ON MURINE LEUKEMIANARA N; MIYAMOTO T; HIRASHIMA K et al.1982; BLOOD; ISSN 0006-4971; USA; DA. 1982; VOL. 60; NO 1; PP. 188-193; BIBL. 16 REF.Article

Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumoursROGALSKA, Aneta; SZWED, Marzena; JOZWIAK, Zofia et al.Mutation research. Genetic toxicology and environmental mutagenesis (Print). 2010, Vol 700, Num 1-2, pp 1-10, issn 1383-5718, 10 p.Article

Characterization of mutations in aclacinomycin a-non-producing Streptomyces galilaeus strains with altered glycosylation patternsRÄTY, Kaj; HAUTALA, Anne; TORKKELL, Sirke et al.Microbiology (Reading). 2002, Vol 148, pp 3375-3384, issn 1350-0872, 10 p., 11Article

Aclarubicin: experimetal and clinical experienceRÖTHIG, H.-J; KRAEMER, H. P; SEDLACEK, H. H et al.Drugs under experimental and clinical research. 1985, Vol 11, Num 2, pp 123-125, issn 0378-6501Article

Absorption, fluorescence and fluorimetric detection limits of naturally occurring quinoid antibiotics and dyesWOLFBEIS, O. S; FÜRLINGER, E.Mikrochimica acta (1966. Print). 1983, Vol 3, Num 5-6, pp 385-398, issn 0026-3672Article

Microbial conversion of anthracycline antibiotics. I: Microbial conversion of aclacinomycin B to aclacinomycin AHOSHINO, T; SEKINE, Y; FUJIWARA, A et al.Journal of antibiotics (Tokyo. 1968). 1983, Vol 36, Num 11, pp 1458-1462, issn 0021-8820Article

Electrochemical behaviour and microdetermination of a new cytostatic agent: the aclacimomycinCHATEAU-GOSSELIN, M; VIRE, J.-C; PATRIARCHE, G. J et al.Mikrochimica acta (1966. Print). 1983, Vol 3, Num 5-6, pp 457-465, issn 0026-3672Article

Studies on the effects of anthracyclines on mitochondrial respiration in vitroSOLAINI, G; RONCA, G; BERTELLI, A et al.Drugs under experimental and clinical research. 1985, Vol 11, Num 2, pp 115-121, issn 0378-6501Article

CHEMICAL MODIFICATION OF ANTHRACYCLINE ANTIBIOTICS. III: 4'''-AMINO, 4'''-ALKYLAMINO AND 4'''-AMIDE DERIVATIVES OF ACLACINOMYCIN ATANAKA H; YOSHIOKA T; SHIMAUCHI Y et al.1981; J. ANTIBIOT.; ISSN 0021-8820; JPN; DA. 1981; VOL. 34; NO 7; PP. 850-855; BIBL. 7 REF.Article

Assessment of the antiinvasive potential of the anthracycline aclacinomycin (Aclarubicin®) in a human fibrosarcoma cell lineADDADI-REBBAH, Salima; POITEVIN, Stephane; FOURRE, Nicolas et al.International journal of oncology. 2004, Vol 24, Num 6, pp 1607-1615, issn 1019-6439, 9 p.Article

La différenciation des cellules tumorales par des anthracyclines = Cell differentiation of tumor cells by anthracyclinsMORCEAU, F.Regard sur la biochimie. 1997, Num 2, pp 38-49, issn 0336-1640Article

Enhanced functional capacity of the peritoneal macrophages as antigen presenting cells after aclacinomycin treatment in miceBRAVO-CUELLAR, A; ASTENGO-OSUNA, C; DANERI-NAVARRO, A et al.Biomedicine & pharmacotherapy. 1997, Vol 51, Num 4, pp 181-184, issn 0753-3322Article

Degree of DNA unwinding caused by the binding of aclacinomycin AUTSUNO, K; TSUBOI, M.Chemical and pharmaceutical bulletin. 1997, Vol 45, Num 10, pp 1551-1557, issn 0009-2363Article

Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus AnthracyclineFUKUSHIMA, Toshihiro; KAWABATA, Hiroshi; TANAKA, Masao et al.Anticancer research. 2012, Vol 32, Num 4, pp 1347-1353, issn 0250-7005, 7 p.Article

Aclacinomycin A-inhibition of phage φX174 DNA synthesis in vitroTANAKA, A; MORITA, J; KOMANO, T et al.Journal of antibiotics (Tokyo. 1968). 1983, Vol 36, Num 7, pp 900-906, issn 0021-8820Article

Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemiaLIMIN LIU; YANMING ZHANG; DEPEI WU et al.International journal of hematology. 2014, Vol 99, Num 5, pp 603-608, issn 0925-5710, 6 p.Article

Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivativesYOUNG, C. W; RAYMOND, V.Cancer treatment reports. 1986, Vol 70, Num 1, pp 51-63, issn 0361-5960Article

NEW ANTICANCER DRUGSKUHN JG; MYERS JW; CALLAHAN SK et al.1982; CANCER CHEMOTHERAPY; ISSN 505242; NLD; DA. 1982; NO 4; PP. 118-139; BIBL. 100 REF.Article

Clinical studies of aclacinomycin A(ACM)MAJIMA, H; OHTA, K.Biomedicine & pharmacotherapy. 1987, Vol 41, Num 5, pp 233-237, issn 0753-3322Article

Sensitive enzyme immunoassay for the quantification of aclacinomycin A using β-D-galactosidase as a labelSOHDA, M; FUJIWARA, K; SAIKUSA, H et al.Cancer chemotherapy and pharmacology. 1985, Vol 14, Num 1, pp 53-58, issn 0344-5704Article

Interaction of anthracycline antibiotics with biopolymers. VIII: Binding parameters of aclacinomycin A to DNAKATENKAMP, U; STUTTER, E; PETRI, I et al.Journal of antibiotics (Tokyo. 1968). 1983, Vol 36, Num 9, pp 1222-1227, issn 0021-8820Article

THE EFFECT OF IN VIVO DOXORUBICIN (ADRIAMYCIN) AND ACLACINOMYCIN ADMINISTRATION ON GUANYLATE CYCLASE ACTIVITY IN RAT TISSUESLEHOTAY DC; LEVEY BA; ROGERSON BJ et al.1981; PROC. SOC. EXP. BIOL. MED.; ISSN 0037-9727; USA; DA. 1981; VOL. 167; NO 4; PP. 459-462; BIBL. 8 REF.Article